IASLC TTLC 2024 | Elucidating the causes behind low testing rates in lung cancer

Debora Bruno, MD, Seidman Cancer Center, Cleveland, OH, gives an overview of limitations to more widespread screening for lung cancer. Issues relating to cost for patients and insurance companies have contributed to low testing rates, especially for next-generation sequencing (NGS). In the case for tissue biopsies, obtaining enough tissue can be an issue, and long turnaround times can be a barrier for clinicians to make timely decisions. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.